Tag Archives: ONCE

Top 5 Bank Stocks To Watch For 2018

Click to enlarge

It is no secret that I’ve been a long term fan of Bank of America (NYSE:BAC). But of late, that patience and faith in the model hasn’t worked out as investors have used the big banks as little more than proxies for whether or not they felt the Fed would raise rates. Indeed, BAC has soared and plummeted countless times over the past couple of years based upon Fed commentary or inaction on rates and that has made holding BAC a sometimes painful process. And after the stock traded in a very defined range for right at two years, BAC broke down out of the range and a complete meltdown ensued. However, there is hope; recent price action has me very excited about what’s to come.

Top 5 Bank Stocks To Watch For 2018: Sanofi(SNY)

Advisors’ Opinion:

  • [By Money Morning Staff Reports]

    The drug is currently in phase 1 of an extensive trial, after which the U.S. Department of Health and Human Services (DHHS) will pass the vaccine on to French pharmaceutical company Sanofi SA (NYSE ADR: SNY). Sanofi will carry out the vaccine’s phase 2 and phase 3 trials because “of the high risk and high costs involved in advanced vaccine development,” the Army wrote in an April 21 public letter on its website.

  • [By Brian Orelli]

    Image source: Getty Images.

    What happened with Alnylam Pharmaceuticals this quarter?
    All of the biotech’s revenue comes from its partners. The upfront payments are often amortized over many years, so the jump in revenue is nothing to get excited about. The big news during the quarter was the decision to stop development of revusiran after a phase 3 trial in patients with ATTR amyloidosis showed more patients taking revusiran died than those taking placebo. APOLLO, a phase 3 trial testing patisiran in patients with polyneuropathy due to hereditary ATTR amyloidosis, is due to read out in the middle of this year, hopefully leading to a marketing application filed with the FDA by the end of the year. Data presented for its hemophilia and other bleeding disorders drug, fitusiran, were positive, leading partner Sanofi (NYSE:SNY) to exercise its right to co-develop and co-promote fitusiran with Alnylam in the U.S., Canada, and Western Europe. Sanofi already had commercial rights to the rest of the world. The duo plans to start a phase 3 program for fitusiran in early 2017. The Medicines Company (NASDAQ:MDCO) presented more positive data for their cholesterol-lowering drug inclisiran, which was called ALN-PCSsc before Alnylam out-licensed the drug. The Medicines Company is running a new phase 2 trial in patients with a genetic disease that causes extremely high levels of cholesterol, and plans to start a phase 3 program in the middle of this year.

    What management had to say

    The APOLLO results, combined with starting phase 3 trials for fitusiran and inclisiran, puts Alnylam in a good position for years to come. CEO John Maraganore explained: “This potentially positions Alnylam to have a steady flow of phase 3 readouts, and if positive, commercial launches on essentially an annual basis going forward.”

  • [By Ben Levisohn]

    Hopes were high for MannKind (MNKD) when its inhaled insulin Afrezza was approved by the FDA more than two years ago. At the time, Barron’s warned that it was time to dump MannKind’s shares, something that now seems prescient, as its shares have since tumbled 95%. No wonder, as the news since then has been far from good. MannKind found a partner in Sanofi (SNY), only to get dumped in early 2016, and has since been forced to sell property to raise cash. And now MannKind could be on the verge of being delisted from the Nasdaq due to its sub $1 stock price. What now? Piper Jaffray’sJoshua Schimmer and team see a reverse stock split in MannKind’s future:

  • [By Diane Alter]

    Basically, the Phab 2 Pro allows users more ways to explore no matter where they are or go. Lenovo shares were 1.82% at $12.89 in today’s (Thursday) morning session.

    CES Companies to Watch, No. 4: Sony (NYSE: SNY)

    Sony Corp ADR (NYSE: SNE) ventured into the OLED television space with its new A1E series unveiling. The new TVs come in 55, 65, and 77 inch sizes, run on Android, and work with Google Home. Sony said that moving to OLED allows it to offer a TV with “unprecedented black levels, rich and lifelike color, dynamic contrast, blur-less image, and a wide viewing angle.”

  • [By William Romov]

    And there’s a dividend stock on this list with an even higher yield…

    Best Dividend Stocks for Retirees No. 1: Sanofi (NYSE: SNY)

    Join the conversation. Click here to jump to comments…

  • [By Brian Feroldi]

    Shares of Flexion Therapeutics (NASDAQ:FLXN) rose by more than 33% at$26.28 in Thursday trading, in response to rumors that a takeover bid from Sanofi (NYSE:SNY) is looming.

Top 5 Bank Stocks To Watch For 2018: Spark Therapeutics, Inc.(ONCE)

Advisors’ Opinion:

  • [By Jim Robertson]

    On Wednesday, our Elite Opportunity Pronewsletter suggested going long again on small cap gene therapy stock Spark Therapeutics (NASDAQ: ONCE):

    Financially, Spark Therapeutics has over $300M in cash on the books and no debt to speak of yet, which equates to a share price of just over four times cash. The Company has generated over $20M in revenue for the trailing twelve months, and although the Company is expected to continue to lose money for the next few years, any strong clinical data that hits the tape could rocket shares of ONCE overnight, just like we’ve seen with so many others over the years.

  • [By Paul Ausick]

    Spark Therapeutics Inc. (NASDAQ: ONCE) dropped 44% Monday to post a new 52-week low of $41.06 after closing at $73.38 on Friday. The 52-week high is $91.75. Volume was around 13.5 million, nearly 30 times the daily average of about 480,000. The company’s hemophilia A drug posted disappointing trial results.

  • [By Chris Lange]

    Spark Therapeutics Inc. (NASDAQ: ONCE) saw its shares take a big step back on Monday after the firm reported less than favorable results at the American Society of Hematology (ASH) annual meeting. Analysts have taken this opportunity to weigh in on the stock:

  • [By Lisa Levin]

    Shares of Spark Therapeutics Inc (NASDAQ: ONCE) were down 36 percent to $47.08 on preliminary SPK-8011 trial data.

    Athenex Inc (NASDAQ: ATNX) was down, falling around 13 percent to $13.95. Almirall and Athenex reported a strategic partnership to develop and commercialize KX2-391 in the U.S. and Europe.

Top 5 Bank Stocks To Watch For 2018: Genesis Energy, L.P.(GEL)

Advisors’ Opinion:

  • [By Lisa Levin]

    Breaking news

    Lennar Corporation (NYSE: LEN) reported better-than-expected profit for its first quarter on Tuesday.
    General Mills, Inc. (NYSE: GIS) reported upbeat earnings for its fiscal third quarter, while sales missed estimates.
    Genesis Energy, L.P. (NYSE: GEL) disclosed that it has priced its public offering of 4 million common units for gross proceeds of $124 million.
    South State Corporation (NASDAQ: SSB) reported that it has increased its buyback plan from 250,000 shares to 1 million shares.

Top 5 Bank Stocks To Watch For 2018: iShares PHLX SOX Semiconductor Sector Index Fund(SOXX)

Advisors’ Opinion:

  • [By Peter Graham]

    A long term performance chart shows Marvell Technology Group giving investors and traders a bit of a roller-coaster ride while peerSTMicroelectronics NV (NYSE: STM) and ETF benchmarks SPDR S&P Semiconductor ETF (NYSEARCA: XSD) and iShares PHLX SOX Semiconductor Sector (NASDAQ: SOXX) really took off last year:

  • [By Peter Graham]

    A long term performance chart shows Marvell Technology Group along with peersSTMicroelectronics NV (NYSE: STM) and ETF benchmarks SPDR S&P Semiconductor ETF (NYSEARCA: XSD) and iShares PHLX SOX Semiconductor Sector (NASDAQ: SOXX)all taking offlast year albeit MRVL has underperformed ETF benchmarks:

  • [By Peter Graham]

    A long term performance chart shows Marvell Technology Group under performingpeersSTMicroelectronics NV (NYSE: STM) and ETF benchmarks SPDR S&P Semiconductor ETF (NYSEARCA: XSD) and iShares PHLX SOX Semiconductor Sector (NASDAQ: SOXX)will all taking offlast year:

  • [By Peter Graham]

    A long term performance chart shows Marvell Technology Group peaking in early 2015 while peerSTMicroelectronics NV (NYSE: STM) hasnt performed much better and ETF benchmarks SPDR S&P Semiconductor ETF (NYSEARCA: XSD) and iShares PHLX SOX Semiconductor Sector (NASDAQ: SOXX) have performed better:

  • [By Peter Graham]

    A long term performance chart shows Marvell Technology Group in an uptrend for the past two year, but also under performingpeerSTMicroelectronics NV (NYSE: STM) and ETF benchmarks SPDR S&P Semiconductor ETF (NYSEARCA: XSD) and iShares PHLX SOX Semiconductor Sector (NASDAQ: SOXX):

Top 5 Bank Stocks To Watch For 2018: SBA Communications Corporation(SBAC)

Advisors’ Opinion:

  • [By Craig Jones]

    On CNBC's "Fast Money Halftime Report", Jon Najarian shared with the viewers an options trading idea in SBA Communications Corporation (NASDAQ: SBAC). He noticed big call options volume in the name and he thinks it would be a good idea to get a long position.

  • [By Paul R. La Monica]

    And the infrastructure fund has stakes in cell phone tower owners Crown Castle (CCI) and SBA Communications (SBAC), as well as giant British gas and electric utility National Grid (NGG).

Top 10 Bank Stocks For 2018

Warren Buffett, Wells Fargo’s biggest fan, says the Federal Reserve is making him reduce his stake in the embattled bank.

Buffett’s Berkshire Hathaway (BRKB) disclosed in a regulatory filing on Wednesday that it sold 7.1 million shares of Wells Fargo (WFC) for $384 million this week. It intends to sell an additional 1.7 million shares of Wells soon.

Berkshire’s stake in the bank had climbed above 10%. That would trigger Fed restrictions on how much business Berkshire can do with the bank. The company is selling stock to bring its stake back below 10%.

Shares of Wells Fargo fell slightly in after-hours trading Wednesday following the disclosure. They fell even more in pre-market trading Thursday after the company reported flat earnings in the first quarter.

Wells has been hammered in the last year, since the bank admitted that its employees created millions of unauthorized accounts for clients in order to meet sales quotas at the bank. Buffett has stood by the bank, calling it an “incredible institution” that had made a “terrible mistake.”

Top 10 Bank Stocks For 2018: CytRx Corporation(CYTR)

Advisors’ Opinion:

  • [By Roberto Pedone]

    Another under-$10 biotechnology player that’s starting to trend within range of triggering a major breakout trade is CytRx (CYTR), which has an oncology pipeline that includes two programs in clinical development for cancer indications: aldoxorubicin and tamibarotene. This stock has been moving to the upside during the last three months, with shares up by 21%.

    If you take a look at the chart for CytRx, you’ll notice that this stock has been trending sideways inside of a consolidation chart pattern for the last two months, with shares moving between $2.27 on the downside and $2.68 on the upside. That consolidation pattern has occurred right above this stock’s 50-day and 200-day moving averages. Shares of CYTR have now started to break out above some near-term overhead resistance at $2.49 a share. That move is quickly pushing CYTR within range of triggering an even bigger breakout trade above the upper-end of its recent sideways trading chart pattern.

    Market players should now look for long-biased trades in CYTR if it manages to break out above some near-term overhead resistance levels at $2.68 to $2.80 a share with high volume. Look for a sustained move or close above those levels with volume that registers near or above its three-month average action of 154,838 shares. If that breakout triggers soon, then CYTR will set up to re-test or possibly take out its next major overhead resistance levels at $3.20 to $4 a share.

    Traders can look to buy CYTR off any weakness to anticipate that breakout and simply use a stop that sits right below its 200-day at $2.33 a share or below more support at $2.27 a share. One can also buy CYTR off strength once it clears those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.

Top 10 Bank Stocks For 2018: Gol Linhas Aereas Inteligentes S.A.(GOL)

Advisors’ Opinion:

  • [By Monica Gerson]

    Gol Linhas Aereas Inteligentes SA (ADR) (NYSE: GOL) is expected to post a quarterly loss at $0.73 per share on revenue of $705.31 million.

    Caretrust REIT Inc (NASDAQ: CTRE) is estimated to post its quarterly earnings at $0.26 per share on revenue of $22.21 million.

  • [By Lisa Levin]

    Regional Airlines: The industry dropped 1.9 percent by 11:00 am. The worst performer in this industry was Gol Linhas Aereas Inteligentes SA (ADR) (NYSE: GOL), which declined 5.8 percent.

  • [By Dan Caplinger]

    Yet some stocks didn’t participate in the rally, instead contending with negative news of their own. Zoe’s Kitchen (NYSE:ZOES), GOL Lineas Aereas Inteligentes (NYSE:GOL), and Sarepta Therapeutics (NASDAQ:SRPT) were among the worst performers on the day. Below, we’ll look more closely at these stocks to tell you why they did so poorly.

Top 10 Bank Stocks For 2018: Spark Therapeutics, Inc.(ONCE)

Advisors’ Opinion:

  • [By Paul Ausick]

    Spark Therapeutics Inc. (NASDAQ: ONCE) dropped 44% Monday to post a new 52-week low of $41.06 after closing at $73.38 on Friday. The 52-week high is $91.75. Volume was around 13.5 million, nearly 30 times the daily average of about 480,000. The company’s hemophilia A drug posted disappointing trial results.

  • [By Lisa Levin]

    Shares of Spark Therapeutics Inc (NASDAQ: ONCE) were down 36 percent to $47.08 on preliminary SPK-8011 trial data.

    Athenex Inc (NASDAQ: ATNX) was down, falling around 13 percent to $13.95. Almirall and Athenex reported a strategic partnership to develop and commercialize KX2-391 in the U.S. and Europe.

  • [By Jim Robertson]

    On Wednesday, our Elite Opportunity Pronewsletter suggested going long again on small cap gene therapy stock Spark Therapeutics (NASDAQ: ONCE):

    Financially, Spark Therapeutics has over $300M in cash on the books and no debt to speak of yet, which equates to a share price of just over four times cash. The Company has generated over $20M in revenue for the trailing twelve months, and although the Company is expected to continue to lose money for the next few years, any strong clinical data that hits the tape could rocket shares of ONCE overnight, just like we’ve seen with so many others over the years.

Top 10 Bank Stocks For 2018: Jacobs Engineering Group Inc.(JEC)

Advisors’ Opinion:

  • [By Chris Lange]

    The stock posting the largest daily percentage gain in the S&P 500 ahead of the close Tuesday was Jacobs Engineering Group Inc. (NYSE: JEC) which rose about 9% to $64.92. The stocks 52-week range is $49.31 to $65.29. Volume was1.8 million compared to its average volume of less than 1 million.

  • [By Ben Levisohn]

    Lee offers 22 stocks that could benefit from the correlation trade: Western Digital (WDC), Xerox (XRX), First Solar, Ford Motor, Best Buy (BBY), PulteGroup (PHM), AutoNation (AN), Textron (TXT), Jacobs Engineering Group (JEC), Mosaic, BB&T (BBT), Fifth Third Bancorp (FITB),Loews (L), Regions Financial (RF), KeyCorp (KEY), Comerica (CMA), Leucadia National (LUK), Zions Bancorp (ZION), Valero Energy (VLO), Marathon Oil, Cardinal Health (CAH), and Pepco Holdings (POM).

Top 10 Bank Stocks For 2018: Autohome Inc.(ATHM)

Advisors’ Opinion:

  • [By Monica Gerson]

    Autohome Inc (ADR) (NYSE: ATHM) is estimated to report its quarterly earnings at $1.68 per share on revenue of $1.05 billion.

    Vera Bradley, Inc. (NASDAQ: VRA) is expected to report its quarterly earnings at $0.05 per share on revenue of $106.75 million.

  • [By R. Chandrasekaran]

    The following stocks are rated with Neutral:

    JD.Com Inc(ADR) (NASDAQ: JD). Vipshop Holdings Ltd – ADR (NYSE: VIPS). Autohome Inc (ADR) (NYSE: ATHM). SouFun Holdings Ltd (NYSE: SFUN). Leju Holdings Ltd (ADR) (NYSE: LEJU).
    Underweight Names

    The following stocks are rated Underweight:

Top 10 Bank Stocks For 2018: Medical Marijuana, Inc. (MJNA)

Advisors’ Opinion:

  • [By Peter Graham]

    A long term performance chart shows GW Pharmaceuticals PLC outperforming other marijuana stocks like Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE), Cannabis Science Inc (OTCMKTS: CBIS) and Medical Marijuana Inc (OTCMKTS: MJNA), but shares are also once again falling off from all-time highs:

  • [By Keith Speights]

    As increasingly more marijuana growers entered the market and more states allowed residents to legally grow marijuana, cannabis prices dropped throughout 2016. Wholesale marijuana prices late in the year were roughly half the levels of 12 months earlier. Will this trend continue — and possibly hurt leading marijuana stocks including Aphria (NASDAQOTH:APHQF),Aurora Cannabis (NASDAQOTH:ACBFF), Medical Marijuana,Inc.(NASDAQOTH:MJNA), and even GW Pharmaceuticals (NASDAQ:GWPH) in the process?

  • [By Matthew Briar]

    Look out Cannabis Science Inc (OTCMKTS:CBIS), and step aside Medical Marijuana Inc (OTCMKTS:MJNA). There’s a new cannabis name on the scene…. Algae Dynamics Corp. (OTCMKTS:ADYNF). It may not be known (or named) like its marijuana peers, but give it time. This small cap company has a very big idea, and it’s going to sprout soon.

    Yes, Algae Dynamics is an algae company. It’s not just an algae company though.

    Algae Dynamics is the owner of the proprietary BioSilo ™ process. BioSilo is a way of growing algae quickly and effectively…. a mix of an open-pond system and a photobioreactor, which is a light-driven approach to growing algae. It can be viewed as a “best of both worlds” approach, lowering the typical cost of algae farming, while the modular design makes it easy to maintain.

    The company could go a lot of directions with the technology, Most of the tens of thousands of species of algae are rather flexible in how they can be purposed, and what they can become. Algae Dynamics is first focused on the development of two kinds of products though…. Chlorella, and Omega-3.

    Chlorella is a type of microalgae that can be processed into a consumable powder by drying it until it takes a powder form, similar to coffee. Chlorella is rich in minerals, prebiotics, vitamins, and other nutritional substances. It can be added to a baked goods and a number of other products, or taken as a supplement on its own. Chlorella is used in over 1,000 products in the food and beverage markets. Algae Dynamics estimates the global Chlorella market was $210.3 million in 2014 and is expected to reach $265.5 million in 2018.

    Despite a market for Chlorella in North America, there are no commercial North American producers of it.

    Due to its health benefits, Omega-3 oil can be added to a very wide range of products. Consumers are increasingly aware of these benefits too, leading to substantial growth in the industry; health supplements compr

Top 10 Bank Stocks For 2018: Inter Parfums, Inc.(IPAR)

Advisors’ Opinion:

  • [By Monica Gerson]

    Inter Parfums, Inc. (NASDAQ: IPAR) is estimated to post its quarterly earnings at $0.31 per share on revenue of $110.58 million.

    Norwegian Cruise Line Holdings Ltd (NASDAQ: NCLH) is expected to report its quarterly earnings at $0.37 per share on revenue of $1.10 billion.

Top 10 Bank Stocks For 2018: SeaWorld Entertainment, Inc.(SEAS)

Advisors’ Opinion:

  • [By Jon C. Ogg]

    SeaWorld Entertainment Inc. (NYSE: SEAS) was downgraded to Sell from Neutral and the price target was cut to $15 from $19 (versus an $18.88 close) at Citigroup.

  • [By WWW.THESTREET.COM]

    SeaWorld Entertainment (SEAS) is probably the most famous example of a company that’s suffered from animal cruelty allegations. Shares of the theme park operator, backed by Blackstone (BX) , have never recovered from the release of the 2013 documentary Blackfish, which argued that orca captivity is inhumane and dangerous to the human trainers of the orcas. SeaWorld announced in March that it would phase out its orca captivity, breeding and live shows. The company’s remaining whales, most of which were born in captivity, will live out their lives at the parks. The news sent SeaWorld shares soaring 9%, but continued attendance drops forced the company to slash its dividend and invest $175 million in new attractions.

  • [By Ben Levisohn]

    SeaWorld Entertainment (SEAS) has dropped 2.2% to $18.47 after getting cut to Sell from Neutral at Citigroup.

    Valeant Pharmaceuticals International (VRX) has jumped 4.3% to $11.68 after activist investor ValueAct bought three million shares of the beaten-down specialty pharmaceutical company.

  • [By Peter Graham]

    The Q4 2016 earnings report for troubled small capSeaWorld Entertainment Inc (NYSE: SEAS) is scheduled for before the market opens onTuesday (February 28th) as the company still grapples with thefallout generated from the highly critical documentary Blackfish. On Tuesday, SeaWorld Entertainment reportedthat preliminary total 2016 revenues were expected to be $1.344 billion and total attendance was approximately 22.0 million guests for the year. The CEO commented:

  • [By Benzinga News Desk]

    In the parched terrain just south of the United States border, the prices of food and other necessities follow the dollar, whose value has been climbing: Link

    ECONOMIC DATA
    Industrial Production (MoM) for Feb 0.00% vs 0.20% consensus estimate; Manufacturing Outputs (MoM) for Feb 0.50% vs 0.40% consensus estimate.
    The University of Michigan's consumer sentiment index for March is schedule for release at 10:00 a.m. ET.
    The index of leading economic indicators for February will be released at 10:00 a.m. ET.
    The Baker Hughes North American rig count report for the latest week is schedule for release at 1:00 p.m. ET.
    ANALYST RATINGS
    Wunderlich upgraded Adobe Systems (NASDAQ: ADBE) from Hold to Buy
    FBR Capital upgraded L Brands (NYSE: LB) from Market Perform to Outperform
    Morgan Stanley upgraded Dean Foods (NYSE: DF) from Neutral to Overweight
    Baird downgraded Patheon (NYSE: PTHN) from Outperform to Neutral
    Citigroup downgraded SeaWorld Entertainment Inc (NYSE: SEAS) from Neutral to Sell
    Goldman Sachs downgraded Macerich (NYSE: MAC) from Neutral to Sell

    This is a tool used by the Benzinga News Desk each trading day — it's a look at everything happening in the market, in five minutes. To get the full version of this note every morning, click here or email minutes@benzinga.com.

  • [By Rick Munarriz]

    It’s time to see if SeaWorld Entertainment (NYSE:SEAS) can earn a treat by performing a fancy trick above water. The struggling theme park operator has a media event slated for Thursday morning at its flagship SeaWorld Orlando park. Speculation centers around the unveiling of a new sea-rescue-themed attraction, but some brand bashers hope that SeaWorld will be taking additional steps to wean itself from live marine-life entertainment.

Top 10 Bank Stocks For 2018: Addus HomeCare Corporation(ADUS)

Advisors’ Opinion:

  • [By Lisa Levin] Gainers
    Marathon Patent Group Inc (NASDAQ: MARA) shares rose 47.1 percent to $3.22 in pre-market trading after jumping 54.23 percent on Wednesday.
    Digital Power Corporation (NYSE: DPW) rose 27.6 percent to $0.800 in pre-market trading after gaining 9.79 percent on Wednesday.
    Social Reality Inc (NASDAQ: SRAX) shares rose 23.1 percent to $7.16 in the pre-market trading session after surging 37.59 percent on Wednesday.
    China Auto Logistics Inc (NASDAQ: CALA) rose 16.9 percent to $4.15 in pre-market trading after gaining 4.11 percent on Wednesday.
    Riot Blockchain Inc (NASDAQ: RIOT) rose 15.1 percent to $18.40 in pre-market trading after climbing 42.01 percent on Wednesday.
    Seven Stars Cloud Group Inc (NASDAQ: SSC) rose 14.5 percent to $2.85 in the pre-market trading session after gaining 0.40 percent on Wednesday.
    Affimed NV (NASDAQ: AFMD) shares rose 14.3 percent to $2.40 in pre-market trading after gaining 4.88 percent on Wednesday.
    Corecivic Inc (NYSE: CXW) rose 10.2 percent to $25.56 in pre-market trading after climbing 0.65 percent on Wednesday.
    LM Funding America, Inc. (NASDAQ: LMFA) rose 9.6 percent to $3.30 in pre-market trading after surging 34.98 percent on Wednesday.
    U.S. Global Investors, Inc. (NASDAQ: GROW) rose 7.2 percent to $3.30 in pre-market trading after dropping 8.06 percent on Wednesday.
    Xunlei Ltd (NASDAQ: XNET) rose 6.8 percent to $25.61 in pre-market trading after climbing 11.74 percent on Wednesday.
    Net 1 UEPS Technologies Inc (NASDAQ: UEPS) shares rose 5.9 percent to $13.00 in pre-market trading after gaining 21.34 percent on Wednesday.
    Addus Homecare Corporation (NASDAQ: ADUS) rose 5.5 percent to $35.60 in pre-market trading after gaining 3.69 percent on Wednesday.
    TOP SHIPS Inc (NASDAQ: TOPS) rose 5.2 percent to $0.528 in pre-market trading after falling 10.36 percent on Wednesday.
    Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA) rose 4.7 percent to $14.11 in pre-market trading. Teva Pharma

Top 10 Bank Stocks For 2018: Energy Focus, Inc.(EFOI)

Advisors’ Opinion:

  • [By Peter Graham]

    Meanwhile, small cap Energy Focus Inc (NASDAQ: EFOI) calls itself an industry-leading innovator of energy-efficient LED lighting technology that aims to be the trusted leader in LED lighting retrofit. As the creator of the first, and so far, only UL-verified low-flicker LED products on the U.S. market, Energy Focus products provide extensive energy and maintenance savings, and aesthetics, safety, health and sustainability benefits over conventional lighting. Customers include national, state and local U.S. government agencies (thanks to numerous research and development projects for the DOE and DARPA) as well as Fortune 500 companies, the U.S. Navy and many others.

  • [By Lisa Levin]

    Shares of Energy Focus Inc (NASDAQ: EFOI) were down 40 percent to $7.95 after the company reported weaker-than-expected Q4 results.

    Omega Protein Corporation (NYSE: OME) was down, falling around 20 percent to $17.47 after the company reported weaker-than-expected results for its fourth quarter.

10 Stocks to Buy for Surefire Gains in 2018 and Beyond

With everyone looking ahead now to 2018, investors are getting bombarded with ideas regarding the best stocks to buy.

Everyone has their own suggestion about which stocks are going to hit the big time in the coming months, but fear not! Here we have a list of 10 sure-fire winners that tick all the boxes. These stocks to buy are not purely subjective. Instead, they have big support from the Street’s top analysts and the upside potential to match based on the average analyst price target.

I found these stocks using a nifty Top Analyst Stocks tool on TipRanks. This pulls up stocks with bullish recent ratings from multiple top analysts. Scanning through this list, I was able to identify 10 top stocks that make compelling investing opportunities right now. Just to note, I purposefully eliminated stocks that only have big upside potential because share prices are plummeting.

With that in mind, let’s dive in and see which stocks make the cut for 2018:

Stocks to Buy: Micron (MU) Stocks to Buy: Micron (MU)investorplace.com/wp-content/uploads/2017/09/mumsn-300×165.jpg 300w, investorplace.com/wp-content/uploads/2017/09/mumsn-55×30.jpg 55w, investorplace.com/wp-content/uploads/2017/09/mumsn-200×110.jpg 200w, investorplace.com/wp-content/uploads/2017/09/mumsn-162×88.jpg 162w, investorplace.com/wp-content/uploads/2017/09/mumsn-400×220.jpg 400w, investorplace.com/wp-content/uploads/2017/09/mumsn-116×64.jpg 116w, investorplace.com/wp-content/uploads/2017/09/mumsn-100×55.jpg 100w, investorplace.com/wp-content/uploads/2017/09/mumsn-91×50.jpg 91w, investorplace.com/wp-content/uploads/2017/09/mumsn-78×43.jpg 78w,https://investorplace.com/wp-content/uploads/2017/09/mumsn-170×93.jpg 170w” sizes=”(max-width: 728px) 100vw, 728px” />Source: Shutterstock

Over the last three months, semiconductor stock Micron Technology, Inc. (NASDAQ:MU) has received a whopping 19 buy ratings and just 3 hold ratings. As a result, the stock has a ‘Strong Buy’ analyst consensus rating. These analysts believe (on average) that Micron has big upside potential of over 30% from the current share price. This would take MU from $44.12 all the way to $57.65. Bear in mind, MU has already doubled year-to-date!

Five-star Rajvindra Gill assigned a buy rating to MU with a very confident $76 price target on Dec. 20 (72% upside). He says the market is undervaluing MU and he sees serious potential in: 1) 3D NAND transition, which generates a significant cost advantage (30%-35%); and 2) technology limitations in DRAM supply growth.

“We believe investors are focusing too heavily on a NAND pricing decline to see the big picture. With another record quarter and guide (beat revenue and EPS consensus by 5.6% and 11.4%, respectively) in the bag, Micron is on track to generate quarterly EPS of nearly $2.50 or roughly $10 per share of annualized earnings” said Gill on Dec. 20.

Note that this is a top analyst worth following. He is ranked No. 43 out of over 4,700 analysts tracked by TipRanks.

Stocks to Buy: Spark Therapeutics (ONCE)

Stocks to Buy: Spark Therapeutics (ONCE)investorplace.com/wp-content/uploads/2017/08/oncemsn-300×165.jpg 300w, investorplace.com/wp-content/uploads/2017/08/oncemsn-55×30.jpg 55w, investorplace.com/wp-content/uploads/2017/08/oncemsn-200×110.jpg 200w, investorplace.com/wp-content/uploads/2017/08/oncemsn-162×88.jpg 162w, investorplace.com/wp-content/uploads/2017/08/oncemsn-400×220.jpg 400w, investorplace.com/wp-content/uploads/2017/08/oncemsn-116×64.jpg 116w, investorplace.com/wp-content/uploads/2017/08/oncemsn-100×55.jpg 100w, investorplace.com/wp-content/uploads/2017/08/oncemsn-91×50.jpg 91w, investorplace.com/wp-content/uploads/2017/08/oncemsn-78×43.jpg 78w,https://investorplace.com/wp-content/uploads/2017/08/oncemsn-170×93.jpg 170w” sizes=”(max-width: 728px) 100vw, 728px” />

Spark Therapeutic Inc’s (NASDAQ:ONCE) innovative gene therapy has just received a critical approval from the Food and Drug Administration. Excitingly, this is the first gene therapy to restore sight to individuals with a rare inherited eye disease that can cause blindness. The treatment, known as Luxturna, can treat both children and adults. Following the news, three analysts quickly reiterated their Spark buy ratings.

“Today’s approval marks another first in the field of gene therapy — both in how the therapy works and in expanding the use of gene therapy beyond the treatment of cancer,” said FDA commissioner Scott Gottlieb. “This milestone reinforces the potential of this breakthrough approach in treating a wide range of challenging diseases.”

Overall this ‘Strong Buy’ stock has a bullish average analyst price target of $73 (38% upside potential). We don’t know the drug’s price just yet, but Phil Nadeau, a top Cowen & Co analyst, says: “$500,000 per procedure is reasonable for a once-per-lifetime therapy that has the potential to be curative.”

Meanwhile, Raymond James’ Reni Benjamin notes that: “1) with no negative surprises, the label is slightly better than expected, only excluding the use of this gene therapy in infants under 12 months of age; 2) Spark also received a Rare Pediatric Disease Priority Review Voucher, which we estimate is worth approximately $125 million based on recent transactions.”

Stocks to Buy: Alcoa (AA) Stocks to Buy: Alcoa (AA)investorplace.com/wp-content/uploads/2016/06/aamsn-300×165.jpg 300w, investorplace.com/wp-content/uploads/2016/06/aamsn-55×30.jpg 55w, investorplace.com/wp-content/uploads/2016/06/aamsn-200×110.jpg 200w, investorplace.com/wp-content/uploads/2016/06/aamsn-162×88.jpg 162w, investorplace.com/wp-content/uploads/2016/06/aamsn-65×36.jpg 65w, investorplace.com/wp-content/uploads/2016/06/aamsn-100×55.jpg 100w, investorplace.com/wp-content/uploads/2016/06/aamsn-91×50.jpg 91w, investorplace.com/wp-content/uploads/2016/06/aamsn-78×43.jpg 78w, investorplace.com/wp-content/uploads/2016/06/aamsn-170×93.jpg 170w” sizes=”(max-width: 728px) 100vw, 728px” />Source: Josh Hallett via Flickr (Modified)

Pennsylvania-based Alcoa Corp (NYSE:AA) is the world’s sixth largest producer of aluminum with locations all over the world. The stock is catching the attention of investors following a bullish upgrade from Credit Suisse. On Dec. 20, five-star Credit Suisse analyst Curt Woodworth ramped up his price target from $42 to $61. This now suggests 22% upside potential from the current price. Woodworth is anticipating that tighter aluminum supply will push up prices due to alumina and bauxite closures.

“We note three smelters curtailed production last week, and the government is set to sharply increase inspections in January. We expect the aluminum market to tighten into late 1Q-18 as downstream demand sharply recovers.” Plus, China’s increased commitment to environmental policy will further curtail supply according to Woodworth.

Overall, AA has a ‘Strong Buy’ rating, with only buy ratings from top analysts in the last three months. At the same time, the average analyst price target of $60 stands at 20% upside from the current share price.

Stocks to Buy: MasTec (MTZ) Stocks to Buy: MasTec (MTZ)investorplace.com/wp-content/uploads/2017/01/mtzmsn-300×165.jpg 300w, investorplace.com/wp-content/uploads/2017/01/mtzmsn-55×30.jpg 55w, investorplace.com/wp-content/uploads/2017/01/mtzmsn-200×110.jpg 200w, investorplace.com/wp-content/uploads/2017/01/mtzmsn-162×88.jpg 162w, investorplace.com/wp-content/uploads/2017/01/mtzmsn-400×220.jpg 400w, investorplace.com/wp-content/uploads/2017/01/mtzmsn-116×64.jpg 116w, investorplace.com/wp-content/uploads/2017/01/mtzmsn-100×55.jpg 100w, investorplace.com/wp-content/uploads/2017/01/mtzmsn-91×50.jpg 91w, investorplace.com/wp-content/uploads/2017/01/mtzmsn-78×43.jpg 78w,https://investorplace.com/wp-content/uploads/2017/01/mtzmsn-170×93.jpg 170w” sizes=”(max-width: 728px) 100vw, 728px” />Source: Shutterstock

Keep a close eye on Florida-based specialty contractor engineer MasTec, Inc. (NYSE:MTZ) in 2018. The company’s work spans electric power infrastructure, oil and natural gas pipelines, renewable energy facilities and wireless networks. Strength across the board has resulted in 100% Street support with seven analysts publishing recent buy ratings. Indeed, MTZ has received no hold or sell ratings from the Street for over 8 months.

“We reiterate a BUY on MTZ ahead of what we expect to be increasing 2018 estimates and an expanding multiple. With all segments poised for growth in 2018, a more diversified positive top line performance is likely to be enhanced on the bottom line by better Oil and Gas margins and a generally improving pricing and mix environment from large projects” writes top Canaccord Genuity analyst Robert Burleson. His buy rating comes with a $58 price tag (15% upside). We can also see that he has an incredible track record on his MTZ ratings with a 100% success rate and 51.6% average return.

Stocks to Buy: TherapeuticsMD (TXMD) Stocks to Buy: TherapeuticsMD (TXMD)investorplace.com/wp-content/uploads/2017/12/txmdmsn-300×165.jpg 300w, investorplace.com/wp-content/uploads/2017/12/txmdmsn-55×30.jpg 55w, investorplace.com/wp-content/uploads/2017/12/txmdmsn-200×110.jpg 200w, investorplace.com/wp-content/uploads/2017/12/txmdmsn-162×88.jpg 162w, investorplace.com/wp-content/uploads/2017/12/txmdmsn-400×220.jpg 400w, investorplace.com/wp-content/uploads/2017/12/txmdmsn-116×64.jpg 116w, investorplace.com/wp-content/uploads/2017/12/txmdmsn-100×55.jpg 100w, investorplace.com/wp-content/uploads/2017/12/txmdmsn-91×50.jpg 91w, investorplace.com/wp-content/uploads/2017/12/txmdmsn-78×43.jpg 78w,https://investorplace.com/wp-content/uploads/2017/12/txmdmsn-170×93.jpg 170w” sizes=”(max-width: 728px) 100vw, 728px” />Source: Shutterstock

I have already banged on about TherapeuticsMD Inc (NASDAQ:TXMD) in my recent piece on top healthcare stocks. But this is an intriguing stock pick that I felt was worth including again. TXMD is a unique biotech making waves in the world of female healthcare. The company develops and commercializes products exclusively for women. Its lead product candidate is the TX-004 soft gel capsule for post-menopausal pain. This approach clearly has the backing of the Street, as TXMD has a Strong Buy analyst consensus rating.

In fact, in the last three months, TherapeuticsMD has received seven back-to-back buy ratings. Plus the $15.30 average analyst price target represents a huge 161% upside from the $6 current share price. Crucially, even the lowest price target of $9 from Noble Financial and Deutsche Bank still suggests 55% upside potential.

The most bullish analyst of the pack is top Cantor Fitzgerald analyst William Tanner. He reiterated his TXMD buy rating on Dec. 19 with a $28 price target. Tanner notes that the FDA has opted to conduct a longer Class 2 review of TX-004. But ultimately, he calls the drug ‘an important new therapy’ for atrophy. He says: “We believe the likelihood of approval is high, 85% probability, the highest we use to account for some revenue forecasting uncertainty.”

Stocks to Buy: Amazon (AMZN) Stocks to Buy: Amazon (AMZN)investorplace.com/wp-content/uploads/2016/05/amznmsn2-300×165.jpg 300w, investorplace.com/wp-content/uploads/2016/05/amznmsn2-55×30.jpg 55w, investorplace.com/wp-content/uploads/2016/05/amznmsn2-200×110.jpg 200w, investorplace.com/wp-content/uploads/2016/05/amznmsn2-162×88.jpg 162w, investorplace.com/wp-content/uploads/2016/05/amznmsn2-65×36.jpg 65w, investorplace.com/wp-content/uploads/2016/05/amznmsn2-100×55.jpg 100w, investorplace.com/wp-content/uploads/2016/05/amznmsn2-91×50.jpg 91w, investorplace.com/wp-content/uploads/2016/05/amznmsn2-78×43.jpg 78w, investorplace.com/wp-content/uploads/2016/05/amznmsn2-170×93.jpg 170w” sizes=”(max-width: 728px)100vw, 728px” />Source: Mike Seyfang via Flickr

Year-to-date Amazon.com, Inc. (NASDAQ:AMZN) has already soared by 56%. But even with shares at $1,176, we can see that the Street still sees AMZN spiking over 11% to $1,311. In fact, in the last three months this stock has received an eyebrow-raising 33 buy ratings vs. just one hold rating.

The most recent rating comes from top RBC Capital analyst Mark Mahaney. He has just carried out a survey on Amazon’s intelligent personal assistant Alexa. And he likes what he sees. “Following our third annual Alexa survey, we are more impressed with the traction of these devices and more convinced of their potential long-term impact. With tens of millions of users and 20K+ skills, we see Alexa’s value prop as becoming increasingly powerful as awareness and ownership ramp. We think AMZN could see $10-$11B in Alexa-related Rev by 2020.”

In fact, recent reports suggest Alexa made a popular holiday gift. On Christmas Day, Amazon’s Alexa app took the No. 1 spots on both the U.S. Google Play and iPhone App Stores’ free app charts.

Stocks to Buy: Comcast (CMCSA) Stocks to Buy: Comcast (CMCSA)investorplace.com/wp-content/uploads/2016/09/cmcsamsn-300×165.jpg 300w, investorplace.com/wp-content/uploads/2016/09/cmcsamsn-55×30.jpg 55w, investorplace.com/wp-content/uploads/2016/09/cmcsamsn-200×110.jpg 200w, investorplace.com/wp-content/uploads/2016/09/cmcsamsn-162×88.jpg 162w, investorplace.com/wp-content/uploads/2016/09/cmcsamsn-65×36.jpg 65w, investorplace.com/wp-content/uploads/2016/09/cmcsamsn-100×55.jpg 100w, investorplace.com/wp-content/uploads/2016/09/cmcsamsn-91×50.jpg 91w, investorplace.com/wp-content/uploads/2016/09/cmcsamsn-78×43.jpg 78w, investorplace.com/wp-content/uploads/2016/09/cmcsamsn-170×93.jpg 170w” sizes=”(max-width: 728px)100vw, 728px” />Source: Mike Mozart via Flickr

The cable sector has been down in the dumps, but it is now looking for a comeback in 2018. And there is one company that stands out in particular: mass media king Comcast Corporation (NASDAQ:CMCSA). In the last three months, Comcast scores 10 out of 10, with 10 consecutive buy ratings from the Street. These analysts have an average price target of $45- 10% upside from the current share price.

Top Pivotal Research analyst Jeffrey Wlodarczak is confident that the stock is setup for a solid 2018. On Dec. 19, he told investors: “Recall, our belief that the cable malaise would be winding down by year-end ’17 and we continue to believe that this is the case. Comcast management’s data guidance raise in 4Q, implied material acceleration in capital returns and ’18 cable EBITDA margin expansion helped alleviate these investor fears.”

Plus, he believes that “the elimination of net neutrality laws, which effectively gave regulatory cover for video/phone competitors to freely use the cable plant, should also help with monetization.” His $50 price target translates into 22% upside potential.

Stocks to Buy: Smart Global Holdings (SGH) Stocks to Buy: Smart Global Holdings (SGH)investorplace.com/wp-content/uploads/2017/12/SGHmsn-300×150.jpg 300w, investorplace.com/wp-content/uploads/2017/12/SGHmsn-768×384.jpg 768w, investorplace.com/wp-content/uploads/2017/12/SGHmsn-60×30.jpg 60w, investorplace.com/wp-content/uploads/2017/12/SGHmsn-200×100.jpg 200w, investorplace.com/wp-content/uploads/2017/12/SGHmsn-400×200.jpg 400w, investorplace.com/wp-content/uploads/2017/12/SGHmsn-116×58.jpg 116w, investorplace.com/wp-content/uploads/2017/12/SGHmsn-100×50.jpg 100w, investorplace.com/wp-content/uploads/2017/12/SGHmsn-78×39.jpg 78w, investorplace.com/wp-content/uploads/2017/12/SGHmsn-800×400.jpg 800w,https://investorplace.com/wp-content/uploads/2017/12/SGHmsn-170×85.jpg 170w” sizes=”(max-width: 950px) 100vw, 950px” />Source: Shutterstock

SGH is a global leader in specialty memory, storage and hybrid solutions for the electronics industry for over 25 years. On the back of a strong beat and raise quarter, three analysts reiterated their Smart Global Holdings Inc (NASDAQ:SGH) buy ratings on Dec. 22. Shares popped 10% on the news. And now these analysts say shares can move another 25% from the current share price to hit $43.

SGH CEO Iain MacKenzie commented that the company enjoyed “strength across the board.” Revenue, gross margin and earnings-per-share all exceeded the high ends of previous guidance. He now has even higher hopes for the coming quarters, due to Brazil and the improving global memory market. Indeed, current strength in Brazil is expected to continue throughout the year as the economy recovers.

Stocks to Buy: Aerie Pharmaceuticals (AERI) Stocks to Buy: Aerie Pharmaceuticals (AERI)investorplace.com/wp-content/uploads/2017/07/biotechmsn-300×165.jpg 300w, investorplace.com/wp-content/uploads/2017/07/biotechmsn-55×30.jpg 55w, investorplace.com/wp-content/uploads/2017/07/biotechmsn-200×110.jpg 200w, investorplace.com/wp-content/uploads/2017/07/biotechmsn-162×88.jpg 162w, investorplace.com/wp-content/uploads/2017/07/biotechmsn-400×220.jpg 400w, investorplace.com/wp-content/uploads/2017/07/biotechmsn-116×64.jpg 116w, investorplace.com/wp-content/uploads/2017/07/biotechmsn-100×55.jpg 100w, investorplace.com/wp-content/uploads/2017/07/biotechmsn-91×50.jpg 91w,https://investorplace.com/wp-content/uploads/2017/07/biotechmsn-78×43.jpg 78w, investorplace.com/wp-content/uploads/2017/07/biotechmsn-170×93.jpg 170w” sizes=”(max-width: 728px) 100vw, 728px” />Source: Shutterstock

Eye disease pharma Aerie Pharmaceuticals Inc (NASDAQ:AERI) received an early holiday gift from the FDA. The US regulatory body has just approved Aerie’s lead product Rhopressa two months ahead of schedule. Aerie is now set to hire a 100-person strong sales force in preparation for launch in 2Q18.

“The FDA has approved Aerie’s Rhopressa drug for the treatment of patients with open angle glaucoma or ocular hypertension. We see this announcement as a positive for the company and also a positive read-through for the potential upcoming approval of Roclatan in 2019,” writes five-star Mizuho analyst Difei Yang.

Intriguingly, she also adds: The approval of Rhopressa reinforces our view that Aerie Pharmaceuticals is a strong takeout candidate.” Yang has an $87 price target on the stock and a very strong AERI track record (86% success rate and 73% average return).

Overall, AERI boasts 100% Street support with 7 buy ratings in the last three months. These analysts believe (on average) that AERI can leap a further 32% in the coming months.

Stocks to Buy: Facebook (FB) Stocks to Buy: Facebook (FB)investorplace.com/wp-content/uploads/2017/11/fbmsn-300×150.jpg 300w, investorplace.com/wp-content/uploads/2017/11/fbmsn-768×384.jpg 768w, investorplace.com/wp-content/uploads/2017/11/fbmsn-60×30.jpg 60w, investorplace.com/wp-content/uploads/2017/11/fbmsn-200×100.jpg 200w, investorplace.com/wp-content/uploads/2017/11/fbmsn-400×200.jpg 400w, investorplace.com/wp-content/uploads/2017/11/fbmsn-116×58.jpg 116w, investorplace.com/wp-content/uploads/2017/11/fbmsn-100×50.jpg 100w, investorplace.com/wp-content/uploads/2017/11/fbmsn-78×39.jpg 78w, investorplace.com/wp-content/uploads/2017/11/fbmsn-800×400.jpg 800w,https://investorplace.com/wp-content/uploads/2017/11/fbmsn-170×85.jpg 170w” sizes=”(max-width: 950px) 100vw, 950px” />Source: Shutterstock

Social media giant Facebook Inc (NASDAQ:FB) has a big catalyst heading its way for 2018. The company has already premiered its ‘Watch’ tab, but 2018 could be the year where it really takes off. (Of course, this is on top of all the stock’s other catalysts like Instagram, WhatsApp and a new Direct messaging app.)

One of TipRanks’ top 100 analysts, Brent Thrill, believes the ‘Watch’ tab is about to make a sizeable impact on user video consumption. He says the tab will drive video engagement alongside improved network effects and sharing. Plus, Facebook’s data-driven approach to content and partner revenue share agreements is the smart way to go. He is now looking for revenue purely from the Watch tab to hit $12 billion in 2022. Thrill’s $225 price target suggests considerable upside of 27% from the current share price.

Strong Buy stock FB has scored 30 buy ratings and just 1 sell rating in the last three months. Meanwhile, the average analyst price target of $210 indicates 19% upside potential.

TipRanks offers investors the latest insight into eight different sectors by tracking the activity of 4,700 analysts, 5,000 financial bloggers and even 37,000 corporate insiders. As of this writing, Harriet Lefton did not hold a position in any of the aforementioned securities.

Compare Brokers

Top 10 Warren Buffett Stocks To Invest In Right Now

Warren Buffett has remained quiet, despite being the largest Wells Fargo (NYSE:WFC) shareholder. Why so quiet? I feel he likely doesn’t agree with WFC’s practices (or doesn’t care), but what’s he really to do? He can’t sell, and buying isn’t a sound idea – this isn’t a generational buying opportunity for WFC.

Click to enlarge

Buffett won’t be riding to the rescue of anything soon, but there’s only a handful of companies with large enough market caps that he can invest in these days. At the same time, Buffett has been taken to task in the past over his ethical decisions (read: a large investment in sugary drink maker Coca-Cola (NYSE:KO), his trailer park business, the Sokol-Lubrizol days, etc.)

Top 10 Warren Buffett Stocks To Invest In Right Now: Gevo, Inc.(GEVO)

Advisors’ Opinion:

  • [By Paul Ausick]

    Gevo Inc. (NASDAQ: GEVO) dropped about 16 Wednesday to post a new 52-week low of $1.33 after closing Tuesday at $1.59. The 52-week high is $27.20. Volume of about 3.5 million was nearly 5 times the daily average of around 760,000 shares traded. On Tuesday the renewable chemicals and biofuels priced a secondary offering of 5.68 million shares at $1.90 per share, and also 570,000 units of three different warrants. Today’s drop was about half the size of Tuesday’s.

Top 10 Warren Buffett Stocks To Invest In Right Now: Halyard Health, Inc.(HYH)

Advisors’ Opinion:

  • [By Nelson Hem]

    Medical products maker Halyard Health Inc (NYSE: HYH) stumbled after its spinoff from paper products giant Kimberly Clark Corp (NYSE: KMB), according to “Halyard Health Shares Look Poised to Double” by David Englander. See why Barron’s thinks its shares could double as this Georgia-based company pursues acquisitions and expands its product lineup.

  • [By Nelson Hem]

    See what Barron’s feels are the prospects for Ingersoll-Rand PLC (NYSE: IR) despite the woes in energy, Michael Kors Holdings Ltd (NYSE: KORS) with its new products and international expansion, the Valvoline spinoff from Ashland Inc (NYSE: ASH), as well as Halyard Health Inc (NYSE: HYH) as it pursues acquisitions and expands its product lineup.

Top 10 Warren Buffett Stocks To Invest In Right Now: Six Flags Entertainment Corporation New(SIX)

Advisors’ Opinion:

  • [By Lee Jackson]

    Six Flags Entertainment Inc. (NYSE: SIX) also recently had a large buyer acquiring more shares of the company. CEO and the President John Duffey bought a total of 25,000 shares of the theme park giant at $59.93 per share. The total for the trade was posted at $1,498,198. The stock closed last Friday at $59.96. The 52-week range for the shares is $45.24 to $62.69. The consensus price target is $62.43.

  • [By WWW.THESTREET.COM]

    All is not lost for retail, however. Cramer continued to recommend the closeout and discount chains like TJX Stores (TJX) , Ollie’s Bargain Outlet (OLLI) and Burlington Stores (BURL) . He was also bullish on those who cater to the millennials, like Six Flags (SIX) , Dave & Busters (PLAY) and Foot Locker (FL) , where trying on shoes never seems to go out of style.

  • [By WWW.THESTREET.COM]

    That’s not to say the consumer never leaves the house, but when they do, they shop for their homes at Home Depot (HD) and Home Goods, the TJX Stores (TJX) chain that’s knocking it out of the park. The consumer is also visiting theme parks like Six Flags (SIX) and Walt Disney (DIS) and they’re also going on Carnival Cruises (CCL) .

Top 10 Warren Buffett Stocks To Invest In Right Now: TransUnion(TRU)

Advisors’ Opinion:

  • [By JJ Kinahan]

    Ready To Shop? A highlight this coming week is Black Friday, and recent data hint that shoppers might be ready. A record 195.9 million consumers now have access to revolving credit such as bank-issued and private label credit cards, TransUnion (NYSE: TRU) said in a recent press release. This is the highest level of revolving credit access since TRU began measuring the variable and is greater than the 192.6 million consumers who had access to such credit products in Q3 2016. “The third quarter of 2017 exhibited a lending market that continued to operate in a stable manner, with consumers continuing to gain access to credit and take advantage of that access,” said Ezra Becker, senior vice president and head of research and consulting for TransUnion, in the press release. “However, we are beginning to see a slowdown in originations, which may be a signal of saturation in the lower-risk credit tiers and some pull-back in lender risk appetite in the higher-risk tiers.” Still, Becker predicted a “robust holiday shopping season.”

Top 10 Warren Buffett Stocks To Invest In Right Now: BioLineRx Ltd.(BLRX)

Advisors’ Opinion:

  • [By Jim Robertson]

    On Friday, our Under the Radar Moversnewsletter suggested small cap clinical-stage biopharmaceutical stockBioline RX Ltd (NASDAQ: BLRX) as a speculative buy:

  • [By William Romov]

    Currently trading at $1.09 per share, BioLine Rx Ltd. (Nasdaq: BLRX) develops a broad range of drug candidates to treat cancer, liver fibrosis, and even dry eye syndrome.

Top 10 Warren Buffett Stocks To Invest In Right Now: Spark Therapeutics, Inc.(ONCE)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of Spark Therapeutics Inc (NASDAQ: ONCE) were down 36 percent to $47.08 on preliminary SPK-8011 trial data.

    Athenex Inc (NASDAQ: ATNX) was down, falling around 13 percent to $13.95. Almirall and Athenex reported a strategic partnership to develop and commercialize KX2-391 in the U.S. and Europe.

  • [By Paul Ausick]

    Spark Therapeutics Inc. (NASDAQ: ONCE) dropped 44% Monday to post a new 52-week low of $41.06 after closing at $73.38 on Friday. The 52-week high is $91.75. Volume was around 13.5 million, nearly 30 times the daily average of about 480,000. The company’s hemophilia A drug posted disappointing trial results.

  • [By Jim Robertson]

    On Wednesday, our Elite Opportunity Pronewsletter suggested going long again on small cap gene therapy stock Spark Therapeutics (NASDAQ: ONCE):

    Financially, Spark Therapeutics has over $300M in cash on the books and no debt to speak of yet, which equates to a share price of just over four times cash. The Company has generated over $20M in revenue for the trailing twelve months, and although the Company is expected to continue to lose money for the next few years, any strong clinical data that hits the tape could rocket shares of ONCE overnight, just like we’ve seen with so many others over the years.

  • [By Chris Lange]

    Spark Therapeutics Inc. (NASDAQ: ONCE) saw its shares take a big step back on Monday after the firm reported less than favorable results at the American Society of Hematology (ASH) annual meeting. Analysts have taken this opportunity to weigh in on the stock:

Top 10 Warren Buffett Stocks To Invest In Right Now: Sina Corporation(SINA)

Advisors’ Opinion:

  • [By Steve Symington]

    Shares ofSINA Corporation(NASDAQ:SINA)rose 25.8% in 2016,according to data from S&P Global Market Intelligence, following a pair of stronger-than-expected quarterly reports from the Chinese internet leader in the second half.

  • [By Leo Sun]

    Warren Buffett famously told investors to be “fearful when others are greedy, and greedy when others are fearful.” Dedicated followers of that mantra would probably dismiss Chinese online media giant SINA (NASDAQ:SINA) — which rallied 120% over the past 12 months to a six-year high — as a “greedy” play.

  • [By Ezra Schwarzbaum]

    It was quickly followed by two other Chinese social media sites: SINA Corp (NASDAQ: SINA) and Momo Inc (ADR) (NASDAQ: MOMO).

    Weibo Responds

    Weibo issued a press release later in the day saying it would cooperate with the State Administration of Press, Publication, Radio, Film and Television.

  • [By Shanthi Rexaline]

    SINA Corp (NASDAQ: SINA), which has a stake in Weibo, also tumbled.

    Weibo confirmed that the State Administration of Press, Publication, Radio, Film and Television of the People’s Republic of China or SAPPRFT has ordered local authorities to take measures to suspend audio and video services of some internet companies.

Top 10 Warren Buffett Stocks To Invest In Right Now: Corrections Corporation of America(CXW)

Advisors’ Opinion:

  • [By Jon C. Ogg]

    Corrections Corporation of America (NYSE: CXW) was trading up 7.8% at $20.97 shortly before Monday’s closing bell. GEO Group Inc. (NYSE: GEO) was up 2.2% at $31.29.

  • [By Wayne Duggan]

    If a potential Trump impeachment appears to be progressing, traders should watch for potential buying opportunities in the following places:

    U.S. companies with primarily domestic exposure and the SPDR S&P 500 ETF Trust (NYSE: SPY).
    Bank stocks and the Financial Select Sector SPDR Fund (NYSE: XLF).
    Prison stocks Corecivic Inc (NYSE: CXW) and The GEO Group Inc (NYSE: GEO).
    Energy and coal stocks, including the Market Vectors Coal ETF (NYSE: KOL).

    __________

  • [By Shanthi Rexaline]

    Height Securities said in a note that the recent drama surrounding Sessions, known as a friend to the industry, has scared the wits out of investors in Corecivic Inc (NYSE: CXW) and The GEO Group Inc (NYSE: GEO).

  • [By Lisa Levin] Gainers
    Marathon Patent Group Inc (NASDAQ: MARA) shares rose 47.1 percent to $3.22 in pre-market trading after jumping 54.23 percent on Wednesday.
    Digital Power Corporation (NYSE: DPW) rose 27.6 percent to $0.800 in pre-market trading after gaining 9.79 percent on Wednesday.
    Social Reality Inc (NASDAQ: SRAX) shares rose 23.1 percent to $7.16 in the pre-market trading session after surging 37.59 percent on Wednesday.
    China Auto Logistics Inc (NASDAQ: CALA) rose 16.9 percent to $4.15 in pre-market trading after gaining 4.11 percent on Wednesday.
    Riot Blockchain Inc (NASDAQ: RIOT) rose 15.1 percent to $18.40 in pre-market trading after climbing 42.01 percent on Wednesday.
    Seven Stars Cloud Group Inc (NASDAQ: SSC) rose 14.5 percent to $2.85 in the pre-market trading session after gaining 0.40 percent on Wednesday.
    Affimed NV (NASDAQ: AFMD) shares rose 14.3 percent to $2.40 in pre-market trading after gaining 4.88 percent on Wednesday.
    Corecivic Inc (NYSE: CXW) rose 10.2 percent to $25.56 in pre-market trading after climbing 0.65 percent on Wednesday.
    LM Funding America, Inc. (NASDAQ: LMFA) rose 9.6 percent to $3.30 in pre-market trading after surging 34.98 percent on Wednesday.
    U.S. Global Investors, Inc. (NASDAQ: GROW) rose 7.2 percent to $3.30 in pre-market trading after dropping 8.06 percent on Wednesday.
    Xunlei Ltd (NASDAQ: XNET) rose 6.8 percent to $25.61 in pre-market trading after climbing 11.74 percent on Wednesday.
    Net 1 UEPS Technologies Inc (NASDAQ: UEPS) shares rose 5.9 percent to $13.00 in pre-market trading after gaining 21.34 percent on Wednesday.
    Addus Homecare Corporation (NASDAQ: ADUS) rose 5.5 percent to $35.60 in pre-market trading after gaining 3.69 percent on Wednesday.
    TOP SHIPS Inc (NASDAQ: TOPS) rose 5.2 percent to $0.528 in pre-market trading after falling 10.36 percent on Wednesday.
    Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA) rose 4.7 percent to $14.11 in pre-market trading. Teva Pharma

Top 10 Warren Buffett Stocks To Invest In Right Now: Data I/O Corporation(DAIO)

Advisors’ Opinion:

  • [By Lisa Levin]

    In trading on Wednesday, technology shares fell 2.51 percent. Meanwhile, top losers in the sector included Autodesk, Inc. (NASDAQ: ADSK), down 15 percent, and Data I/O Corporation (NASDAQ: DAIO) down 13 percent.

Top 10 Warren Buffett Stocks To Invest In Right Now: Aaron's, Inc.(AAN)

Advisors’ Opinion:

  • [By Peter Graham]

    A long term performance chart shows shares of Best Buy Co now outperforming potential peersactive in electronics retailing such asmid capAaron’s, Inc (NYSE: AAN)and small cap CONN’S, Inc (NASDAQ: CONN):

  • [By Peter Graham]

    Small cap consumer electronics retailer Aaron’s, Inc (NYSE: AAN) reportedQ2 2017 earnings before the market opened on Friday. Revenues were $815.6 million versus $789.4 million. Progressive Leasing’s revenue in the second quarter of 2017 increased 25.1% to $373.5 million, revenue for DAMI was $8.5 million versus$5.3 million and overall revenues for the Aaron’s Business decreased 10.7% to $433.6 million. Same store revenues decreased 8.1% during the second quarter of 2017 and customer count on a same store basis was down 4.8%. Company-operated Aaron’s stores had 932,000 customersas ofJune 30, 2017, a 7.2% decrease from the second quarter of 2016. Net earnings were $36.3 million versus $38.5 million. The CEO commented:

  • [By Peter Graham]

    A long term performance chart shows shares of Best Buy Co outperforming potential peersactive in electronics retailing such asmid capAaron’s, Inc (NYSE: AAN)and small cap CONN’S, Inc (NASDAQ: CONN):

  • [By Peter Graham]

    The Q4 2016 earnings report for small cap consumer electronics retailer Aaron’s, Inc (NYSE: AAN) is scheduled for before the market opens onFriday (February 17). Last time around, shares spiked in the high single digits after better-than-expected third quarterearnings.

  • [By Lisa Levin]

    Friday afternoon, the non-cyclical consumer goods & services sector proved to be a source of strength for the market. Leading the sector was strength from Align Technology, Inc. (NASDAQ: ALGN) and Aaron's, Inc. (NYSE: AAN).

  • [By Peter Graham]

    Just this morning, small cap consumer electronics retailer Aaron’s, Inc (NYSE: AAN) reported first quarter earnings that have beat expectations. First quarter revenues were$844.6 million compared with $854.4 million for the first quarter of 2016 whilenet earnings increased to $53.3 million compared with $49.7 million in the prior year period. The CEO commented:

Top 5 Medical Stocks To Invest In Right Now

With increasing legislation legalizing marijuana both in Canada and the United States, companies involved in the development of cannabis for medical and other purposes are gaining attention.

But weed stocks, as they are often referred to, have been taking a beating lately, with data showing that many of the stock dumps are sales by executives of major cannabis companies. Is this profit taking, or a reaction to AG Jeff Sessions, who has been an outspoken opponent of legalized marijuana, implying that he might consider a rollback to restore marijuana laws under federal jurisdiction? Its anybodys guess. But rather than rush to unload a company before it goes up in smoke (see what I did there) its worth taking a look at additional assets that a cannabis company may hold.

Top 5 Medical Stocks To Invest In Right Now: American Assets Trust, Inc.(AAT)

Advisors’ Opinion:

  • [By Markus Aarnio]

    Owens Realty Mortgage’s competitors include American Assets Trust (AAT), Alexandria Real Estate Equities (ARE) and Boston Properties (BXP). American Assets Trust has seen five insider buy transactions and four insider sell transactions this year. American Assets Trust has a dividend yield of 2.78%. Alexandria Real Estate Equities has seen 14 insider sell transactions this year. Alexandria Real Estate Equities has a dividend yield of 4.10%. Boston Properties has seen one insider buy transaction and four insider sell transactions this year. Boston Properties has a dividend yield of 2.43%.

Top 5 Medical Stocks To Invest In Right Now: Old Second Bancorp Inc.(OSBC)

Advisors’ Opinion:

  • [By Lisa Levin]

    Friday afternoon, the financial sector proved to be a source of strength for the market. Leading the sector was strength from Wins Finance Holdings Inc (NASDAQ: WINS) and Old Second Bancorp Inc. (NASDAQ: OSBC).

Top 5 Medical Stocks To Invest In Right Now: Spark Therapeutics, Inc.(ONCE)

Advisors’ Opinion:

  • [By Chris Lange]

    Spark Therapeutics Inc. (NASDAQ: ONCE) saw its shares take a big step back on Monday after the firm reported less than favorable results at the American Society of Hematology (ASH) annual meeting. Analysts have taken this opportunity to weigh in on the stock:

  • [By Jim Robertson]

    On Wednesday, our Elite Opportunity Pronewsletter suggested going long again on small cap gene therapy stock Spark Therapeutics (NASDAQ: ONCE):

    Financially, Spark Therapeutics has over $300M in cash on the books and no debt to speak of yet, which equates to a share price of just over four times cash. The Company has generated over $20M in revenue for the trailing twelve months, and although the Company is expected to continue to lose money for the next few years, any strong clinical data that hits the tape could rocket shares of ONCE overnight, just like we’ve seen with so many others over the years.

  • [By Lisa Levin]

    Shares of Spark Therapeutics Inc (NASDAQ: ONCE) were down 36 percent to $47.08 on preliminary SPK-8011 trial data.

    Athenex Inc (NASDAQ: ATNX) was down, falling around 13 percent to $13.95. Almirall and Athenex reported a strategic partnership to develop and commercialize KX2-391 in the U.S. and Europe.

  • [By Paul Ausick]

    Spark Therapeutics Inc. (NASDAQ: ONCE) dropped 44% Monday to post a new 52-week low of $41.06 after closing at $73.38 on Friday. The 52-week high is $91.75. Volume was around 13.5 million, nearly 30 times the daily average of about 480,000. The company’s hemophilia A drug posted disappointing trial results.

Top 5 Medical Stocks To Invest In Right Now: Graco Inc.(GGG)

Advisors’ Opinion:

  • [By Lisa Levin]

    In trading on Thursday, industrials shares fell by 0.83 percent. Meanwhile, top losers in the sector included Graco Inc. (NYSE: GGG), down 9 percent, and Southwest Airlines Co (NYSE: LUV), down 11 percent.

  • [By Joel Elconin]

    At this time, the only relevant news to the Gold market and Gold stocks was the halt of Graco Inc. (NYSE: GGG), which was down $0.80 at $84.64 and just reopened at $82.20.

Top 5 Medical Stocks To Invest In Right Now: Inphi Corporation(IPHI)

Advisors’ Opinion:

  • [By Lisa Levin]

    Technology shares rose by 1.9 percent in the US market on Friday. Top gainers in the sector included Fabrinet (NYSE: FN), and Inphi Corporation (NYSE: IPHI).

  • [By Roberto Pedone]

    Inphi (IPHI) provides high-speed analog and mixed signal semiconductor solutions for the communications, datacenter and computing markets. This stock closed up 4.7% at $13.25 in Monday’s trading session.

    Monday’s Volume: 838,000

    Three-Month Average Volume: 202,080

    Volume % Change: 378%

    From a technical perspective, IPHI jumped higher here right above some near-term support at $12.44 with heavy upside volume. This stock has been uptrending strong for the last five months, with shares soaring higher from its low of $8.62 to its intraday high of $13.85. During that uptrend, shares of IPHI have been consistently making higher lows and higher highs, which is bullish technical price action. That move briefly pushed shares of IPHI into breakout territory, since the stock flirted with some near-term overhead resistance at $13.50.

    Traders should now look for long-biased trades in IPHI as long as it’s trending above some near-term support at $12.44 and then once it sustains a move or close above its new 52-week high at $13.85 with volume that hits near or above 202,080 shares. If we get that move soon, then IPHI will set up to enter new 52-week-high territory, which is bullish technical price action. Some possible upside targets off that move are its next major overhead resistance levels at $14.79 to $16.94, or possibly even $18.

Hot Casino Stocks To Watch For 2018

The casino sector offers a lot of color beyond the characters one expects to find as their customers according to the movies. Local nuances in Macau, Las Vegas, online gambling, and new areas lead to industry-wide changes and company-level opportunities for investors.

Recent headlines have focused on headwinds in Macau – with revenue down for its third consecutive year but perhaps bottoming – potential tailwinds in Japan, and the possibility of liberalization of online gambling and sports betting laws in the US. That said, the general performance of the sector’s leading lights has not been great.

Hot Casino Stocks To Watch For 2018: Staffing 360 Solutions, Inc.(STAF)

Advisors’ Opinion:

  • [By Bryan Murphy]

    The staffing industry – and the IT staffing industry in particular – is poised for tremendous growth in the foreseeable future, and that rising tide bodes very well for Staffing 360 Solutions Inc. (NASDAQ:STAF).

  • [By Matthew Briar]

    Take it all with a grain of salt, as Staffing 360 Solutions Inc (NASDAQ:STAF) has not confirmed it, and certainly not yet agreed to it. But, the buzz is, Jackson Investment Group is interested in acquiring the up-and-coming IT staffing firm at a price well above yesterday’s closing price. Making the whispers even more credible is the fact that Jackson is already a significant STAF shareholder, providing $7.4 million in funding in January of this year.

    Multiple sources including Reuters and Business Insider are suggesting that Jackson Investment Group has delivered a letter to the management staff of Staffing 360 Solutions in regards to a potential buyout offer of $1.10 per share. The offer is not binding, nor is it non-negotiable. That is to say, Jackson (or JIG) can walk away from the deal, and Staffing 360 Solutions can ask for a better price. Indeed, STAF likely would ask for a higher offer, like most acquisition negotiations, if Staffing 360 Solutions is indeed interested.

    The company is certainly doing its part to become attractive to potential buyers as well as investors. Last quarter, revenue of $47.1 million was up 14%, and gross profits of $8.1 million were higher by 8.4% on a year-over-year basis. Moreover, the net loss of $1.5 million was a marked improvement on the year-ago loss of $3.5 million, and the EBITDA of $1.4 million was about the same. Operating expenses fell from 22% of revenue a year earlier to only 17% last quarter, with more such progress on the way.

    Perhaps most important, Staffing 360 Solutions saw organic growth of 7%, meaning the top line bumped up by that much not because of acquisitions, but because it’s existing divisions expanded their client base and billings by 7%. And, last quarter’s progress has been the norm for several quarters now.

    The market cap is a mere $9.5 million, even with today’s 25% jump in response to the JIG news.

    To what extent Staffing 360 Solutions may ask for a better

  • [By Matthew Briar]

    If there was any lingering doubt about Staffing 360 Solutions Inc (NASDAQ:STAF), it was wiped away today. The IT staffing firm’s second quarter numbers verify the long-standing growth trend is still well intact. Better still, even as the top line rises, expense-cuts supported by all the synergies of its recent acquisitions have allowed the bottom line to improve by even more.

    Even before today’s official Q2 announcement we knew that last quarter’s revenue would roll in at $47.1 million and gross profits would end up at $8.1 million. Those figures were up 14% and 8.4%, respectively. What we didn’t know about STAF until today is that the net loss shrank from $3.4 million a year earlier to only $1.5 million now. EBITDA of $1.4 million was about the same as the EBITDA of $1.3 million generated in the second fiscal quarter of the prior year.

    The progress march continues for Staffing 360 Solutions.

  • [By Matthew Briar]

    It’s not blatantly observable anywhere. But, for anyone willing to connect the dots and do the digging in several places, the message is clear — there’s a huge and fast-growing need for more information technology workers, and that plays right into the hand Staffing 360 Solutions Inc (NASDAQ:STAF) is holding.

    There are several data nuggets that point in the same direction, but perhaps none as telling as the recent finding from technology research outfit IDC, which found that by the end of 2017, two-thirds of the CEOs of Global 2000 companies will have digital transformation at the center of their corporate strategies. How are they going to make that happen? Deloitte recently posted some research of its own that should shed some light on the idea. The giant accounting form observed that “In order to maintain the competitive pace of innovation, companies find themselves engaged in a global war for talent.”

Hot Casino Stocks To Watch For 2018: bluebird bio, Inc.(BLUE)

Advisors’ Opinion:

  • [By Lisa Levin]

    bluebird bio Inc (NASDAQ: BLUE) shares were also up, gaining 22 percent to $209.00 after the company announced updated clinical results from ongoing Phase 1 multicenter study of LentiGlobin gene therapy in severe sickle cell disease at the ASH 2017.

  • [By Todd Campbell]

    After updating investors on its wide-ranging gene therapy research program at a key industry conference early in the month,shares ofbluebird bio(NASDAQ:BLUE) surged 20.7% higher in January,according toS&P Global Market Intelligence.

Hot Casino Stocks To Watch For 2018: PetroShare Corp. (PRHR)

Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    Just one company joined the calendar, micro-cap gunshot detector ShotSpotter (Pending:SSTI), and one micro-cap company filed, DJ Basin E&P PetroShare (OTCQB:PRHR). We had expected more JOBS-Act filers this week as Monday marked the first day to file for companies preparing for post-Memorial Day launches.

Hot Casino Stocks To Watch For 2018: Newcastle Investment Corporation(NCT)

Advisors’ Opinion:

  • [By Lee Jackson]

    Newcastle Investment Corp. (NYSE: NCT) also had a director buying shares this past week. Wesley Edens picked up1 million shares of the stock at a price of $4.37. The total for the trade was posted at $4,370,000. The consensus price target for the stock is $4.50.The company invests in and manages real estate related and other investments. Its stock ended the weekat $4.31.

  • [By Jim Robertson]

    Today, our Under the Radar Moversnewsletter suggested shortingsmall cap debt and golf course REITNewcastle Investment Corp (NYSE: NCT):

    this isn’t apt to become a huge winner, but it’s a high-odds winner.

Hot Casino Stocks To Watch For 2018: Grupo Aeroportuario del Centro Norte S.A.B. de C.V.(OMAB)

Advisors’ Opinion:

  • [By Paul R. La Monica]

    It even owns shares of several airport stocks — including Mexico’s Grupo Aeroportuario del Centro Norte (OMAB) and Grupo Aeroportuario del Sureste (ASR).

Hot Casino Stocks To Watch For 2018: Spark Therapeutics, Inc.(ONCE)

Advisors’ Opinion:

  • [By Paul Ausick]

    Spark Therapeutics Inc. (NASDAQ: ONCE) dropped 44% Monday to post a new 52-week low of $41.06 after closing at $73.38 on Friday. The 52-week high is $91.75. Volume was around 13.5 million, nearly 30 times the daily average of about 480,000. The company’s hemophilia A drug posted disappointing trial results.

  • [By Lisa Levin]

    Shares of Spark Therapeutics Inc (NASDAQ: ONCE) were down 36 percent to $47.08 on preliminary SPK-8011 trial data.

    Athenex Inc (NASDAQ: ATNX) was down, falling around 13 percent to $13.95. Almirall and Athenex reported a strategic partnership to develop and commercialize KX2-391 in the U.S. and Europe.

  • [By Jim Robertson]

    On Wednesday, our Elite Opportunity Pronewsletter suggested going long again on small cap gene therapy stock Spark Therapeutics (NASDAQ: ONCE):

    Financially, Spark Therapeutics has over $300M in cash on the books and no debt to speak of yet, which equates to a share price of just over four times cash. The Company has generated over $20M in revenue for the trailing twelve months, and although the Company is expected to continue to lose money for the next few years, any strong clinical data that hits the tape could rocket shares of ONCE overnight, just like we’ve seen with so many others over the years.

  • [By Chris Lange]

    Spark Therapeutics Inc. (NASDAQ: ONCE) saw its shares take a big step back on Monday after the firm reported less than favorable results at the American Society of Hematology (ASH) annual meeting. Analysts have taken this opportunity to weigh in on the stock:

usa stock exchange

MannKind (MNKD) investors saw Afrezza scripts come in for the week of 11/10 slightly higher than the previous week, but essentially flat. This is a period where traction is needed if MannKind hopes to hit the re-stated low end of net revenue guidance of $6 million. Simply stated, the company needs sales to ramp up substantially in a time period where it is typically tough to demonstrate sales traction with prescription drugs. The data this week is the first data that includes the potential impacts of the regional television advertising campaign launched by MannKind on November 6th. Ad campaigns take time to bring about maximum effectiveness, so investors should not anticipate or expect an overnight shift in script sales. In the near term, patients with existing appointments that see the ad may be compelled to ask their doctor about Afrezza. In the longer term, the benefit may grow because the advertisement may compel a patient to schedule an appointment and inquire. One challenge that remains is that insurance coverage on Afrezza is far from optimal, and while a patient may ask about the drug, they may not act on it after getting a script because of a lack of coverage or the level of out of pocket expense. Like anything, there are positives and negatives to consider so that you as an investor can arrive at a realistic assessment and opinion.

usa stock exchange: Pan American Silver Corp.(PAAS)

Advisors’ Opinion:

  • [By Jim Cramer]

    The company, on the basis of change in net income from the same quarter one year ago, has significantly underperformed when compared to that of the S&P 500 and the Metals & Mining industry. The net income has significantly decreased by 231.0% when compared to the same quarter one year ago, falling from -$20.25 million to -$67.05 million.

     

  • [By Laurie Kulikowski]

    We rate PAN AMERICAN SILVER CORP as a Sell with a ratings score of D. This is driven by some concerns, which we believe should have a greater impact than any strengths, and could make it more difficult for investors to achieve positive results compared to most of the stocks we cover. The company’s weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, weak operating cash flow, generally disappointing historical performance in the stock itself and feeble growth in its earnings per share. 

  • [By JPMorgan]

    The weak silver sentiment has raised PAAS’ dividend yield to 2.8% which we feel is well supported by PAAS’ strong balance sheet and its healthy liquidity position of $566mn. The company is also advancing two growth projects, expected to add 5moz of silver and 128koz of gold pa to its production from 2018. Its costs are also improving, helped by devalued operating currencies and productivity improvements. 

usa stock exchange: ChannelAdvisor Corporation(ECOM )

Advisors’ Opinion:

  • [By Lisa Levin]

    ChannelAdvisor Corp (NASDAQ: ECOM) shares dropped 24 percent to $10.85 following Q4 results. ChannelAdvisor reported Q4 net income of $5.8 million on revenue of $31.8 million.

usa stock exchange: CSX Corporation(CSX)

Advisors’ Opinion:

  • [By Craig Jones]

    On CNBC's Fast Money Halftime Report, Jon Najarian spoke about unusually high options trading activity in CSX Corporation (NASDAQ: CSX). The stock traded around 15 percent higher since the Presidential election and options traders are betting that it is going to jump additional 8 percent. Traders were buying the February 38 calls on Wednesday for approximately $0.80. Najarian decided to follow the trade and he bought a call spread in CSX. He's going to be in the position for a month or two.

  • [By Rich Duprey]

    I ran a screen to identify the best-performing stocks from the S&P 500 in January. The top three performers during the month were Alcoa (NYSE:AA), CSX (NASDAQ:CSX), and NRG Energy (NYSE:NRG). Let’s see why they were the big standouts and whether they can keep it going.

  • [By Brett Hershman]

    The Swiss bank said it was raising first-quarter estimates on four of the six rails it covers, with updated estimates above consensus on Canadian National Railway (USA) (NYSE: CNI), CSX Corporation (NASDAQ: CSX) and Kansas City Southern (NYSE: KSU), which is seen to show upside against low expectations.

  • [By Demitrios Kalogeropoulos]

    As for individual stocks, American Express (NYSE:AXP) and CSX (NASDAQ:CSX)both beat the market following quarterly earnings news.

    Image source: Getty Images.

  • [By Dan Caplinger]

    The railroad business has been tough lately, and companies like CSX (NASDAQ:CSX) have had to deal with the ups and downs of the industrial economy and its impact on shipping volume. Coming into Wednesday’s first-quarter financial report, however, CSX investors were excited about the prospects for a resurgence in the railroad’s growth prospects.

usa stock exchange: Spark Therapeutics, Inc.(ONCE)

Advisors’ Opinion:

  • [By Chris Lange]

    Spark Therapeutics Inc. (NASDAQ: ONCE) saw its shares take a big step back on Monday after the firm reported less than favorable results at the American Society of Hematology (ASH) annual meeting. Analysts have taken this opportunity to weigh in on the stock:

  • [By Jim Robertson]

    On Wednesday, our Elite Opportunity Pronewsletter suggested going long again on small cap gene therapy stock Spark Therapeutics (NASDAQ: ONCE):

    Financially, Spark Therapeutics has over $300M in cash on the books and no debt to speak of yet, which equates to a share price of just over four times cash. The Company has generated over $20M in revenue for the trailing twelve months, and although the Company is expected to continue to lose money for the next few years, any strong clinical data that hits the tape could rocket shares of ONCE overnight, just like we’ve seen with so many others over the years.

  • [By Lisa Levin]

    Shares of Spark Therapeutics Inc (NASDAQ: ONCE) were down 36 percent to $47.08 on preliminary SPK-8011 trial data.

    Athenex Inc (NASDAQ: ATNX) was down, falling around 13 percent to $13.95. Almirall and Athenex reported a strategic partnership to develop and commercialize KX2-391 in the U.S. and Europe.

usa stock exchange: International Game Technology(IGT)

Advisors’ Opinion:

  • [By Dan Caplinger]

    Thursday was another strong day on Wall Street, with major benchmarks posting gains across the board. The S&P 500 reached another all-time high on strength from an upbeat view of the economy and good earnings results from major companies in the retail sector. Although energy prices sagged, investors seemed to focus on the cost savings that consumers would enjoy from cheaper gasoline rather than the profit hit that major oil and natural gas companies might suffer. Still, not every stock participated in the rally, and International Game Technology (NYSE:IGT), Genesco (NYSE:GCO), and Ensco (NYSE:ESV) were among the worst performers on the day. Below, we’ll look more closely at these stocks to tell you why they did so poorly.

  • [By Michael Flannelly]

    Analysts at Sterne Agee noted on Monday that International Game Technology’s (IGT) fiscal 2014 growth is stronger than it appears. As such, the analysts raised the price target on the casino gaming equipment manufacturer.

    The analysts maintain a “Buy” rating on IGT and now see shares reaching $25, up from the previous target of $23. This new price target suggests a 23% upside to the stock’s Friday closing price of $20.32.

    “Excluding FY13 Canadian VLT sales, which do not recur in FY14, consensus FY14 EPS growth is ~14% versus ‘in-print’ consensus EPS growth of ~4%,” Sterne Agee analyst David Bain said. “We believe IGT’s peer-low stock valuation is partly driven by a misinterpretation of forward growth using ‘in-print’ FY14 EPS projections.”

    Futhermore, the firm raised IGT’s fourth quarter EPS estimates from 33 cents to 34 cents.

    IGT shares were inactive during pre-market trading on Monday. The stock is up 43.4% year-to-date.

  • [By Dan Caplinger]

    Yet even though the overall market remained resilient in the face of some threats to positive sentiment among investors, some stocks posted substantial losses. Stratasys (NASDAQ:SSYS), International Game Technology (NYSE:IGT), and Momo (NASDAQ:MOMO) were among the worst performers on the day. Below, we’ll look more closely at these stocks to tell you why they did so poorly.

usa stock exchange: Credicorp Ltd.(BAP)

Advisors’ Opinion:

  • [By Zacks]

    Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
     
    Bank of Nova Scotia (The) (NYSE: BNS): Free Stock Analysis Report
     
    Banco Bilbao Viscaya Argentaria S.A. (NYSE: BBVA): Free Stock Analysis Report
     
    Credicorp Ltd. (NYSE: BAP): Free Stock Analysis Report
     
    Bank of N.T. Butterfield & Son Limited (The) (NTB): Free Stock Analysis Report
     
    To read this article on Zacks.com click here.

Hot Blue Chip Stocks To Invest In Right Now

On Tuesday, stocks closed mixed with a preference for small-caps as they took gains in some blue chips and big-cap stocks.

Profit-taking started immediately, with a divergence of better-quality stocks being sold. Banks and other financials fell 1.4% at the close, while technology gained 0.9% and consumer discretionary rose 0.5%. Eight of the eleven sectors of the 500 lost ground. From the election until Monday most investing was based on the expectations that the new administration will increase fiscal spending and lower corporate tax rates. The goal is to raise interest rates, inflation and promote growth.

Yesterday buying slowed slightly, but floor traders said that consolidations are a good sign and that the “reflation trade” will probably resume again. The chief investment officer at Wells Fargo Private Bank was quoted by The Wall Street Journal who said “there’s a level of optimism I haven’t seen in a while.”

Crude oil WTI fell 0.7% at $45.56 per barrel due to an EIA report that crude oil supplies increased by 5.27 million barrels instead of an estimate of 1.48 million.

Hot Blue Chip Stocks To Invest In Right Now: STORE Capital Corporation(STOR)

Advisors’ Opinion:

  • [By Jim Robertson]

    Mid capretail REIT Store Capital Corp (NYSE: STOR) has just announced that Warren Buffetts Berkshire Hathaway (NYSE: BRK.A; NYSE: BRK.B) has invested $377 million in the company representing 9.8% of total shares outstanding. In the transaction, Store Capital Corp issued 18.6 million shares of company stock in a private placement to a wholly owned subsidiary of Berkshire Hathaway at a price of $20.25 per share. Sharesclosed Mondayup $2.34 or 11.27% to $23.11.The CEO Christopher Volk stated:

  • [By Jason Hall, Brian Stoffel, and Brian Feroldi]

    With that idea in mind, we asked three of our top contributors to write about a stock they see as being a bargain today, and they gave us mortgage industry software lynchpinEllie Mae Inc(NYSE:ELLI), real estate holding companyStore Capital Corp(NYSE:STOR), and steelmaker extraordinaireNucor Corporation(NYSE:NUE).

Hot Blue Chip Stocks To Invest In Right Now: Spark Therapeutics, Inc.(ONCE)

Advisors’ Opinion:

  • [By Jim Robertson]

    On Wednesday, our Elite Opportunity Pronewsletter suggested going long again on small cap gene therapy stock Spark Therapeutics (NASDAQ: ONCE):

    Financially, Spark Therapeutics has over $300M in cash on the books and no debt to speak of yet, which equates to a share price of just over four times cash. The Company has generated over $20M in revenue for the trailing twelve months, and although the Company is expected to continue to lose money for the next few years, any strong clinical data that hits the tape could rocket shares of ONCE overnight, just like we’ve seen with so many others over the years.

Hot Blue Chip Stocks To Invest In Right Now: Northrop Grumman Corporation(NOC)

Advisors’ Opinion:

  • [By Elizabeth Balboa]

    An official government strategy may open the door for defense contractors beyond the traditional Lockheed Martin Corporation (NYSE: LMT), Northrop Grumman Corporation (NYSE: NOC) and United Technologies Corporation (NYSE: UTX).

  • [By Money Morning News Team]

    The No. 3 defense stock to watch is Northrup Grumman Corp. (NYSE: NOC).

    NOC has three primary units: Aerospace Systems, Electronic Systems, and Information Systems.

  • [By Rich Smith]

    Also included in the DSCA’s list of pending contracts are two directed toward the NATO Support and Procurement Agency, specifically:

    A $300 million sale of C-17Globemaster III logistics support services, with Boeing acting as prime contractor; and A $33.5 million sale of Large Aircraft Infrared Countermeasures (LAIRCM) components, used to protect C-17s from anti-aircraft missile attack, supplied by Northrop Grumman (NYSE:NOC).

    Add them all up, and the global shopping list for U.S. arms comes to more than $2.6 billion in total value, with most of that going to benefit prime contractors Orbital ATK and Raytheon, Boeing, Textron, and Northrop Grumman — some of the largest defense contractors on the planet, and stalwarts of the U.S. defense industry, each and every one.

  • [By Jim Robertson]

    Last Monday, U.S. defense contractor Northrop Grumman Corporation (NYSE: NOC) announced it would buy Orbital ATK Inc (NYSE: OA), a direct Aerojet Rocketdyne competitor,for about $7.8 billion (a 22% premium to Orbital’s Friday close) in a deal thatwill give it greater access to lucrative government contracts and expand its arsenal of missile defense systems and space rockets. While Northrop already has a significant presence in payloads, it has not had launcher capability, an area that Orbital brings for both space and missile defense. Orbital also has contracts with NASA and the U.S. Army. The all-cash transaction is the biggest in the defense sector in two years and comes ahead of planned upgrades of U.S. ballistic systems (as the saber rattling by North Korea continues), which are expected to drive demand for missiles.

  • [By Wayne Duggan]

    Aggressive military and law enforcement spending could be good news for Northrop Grumman Corporation (NYSE: NOC), United Technologies Corporation (NYSE: UTX), Lockheed Martin Corporation (NYSE: LMT), TASER International, Inc. (NASDAQ: TASR) and Digital Ally, Inc. (NASDAQ: DGLY).

Hot Blue Chip Stocks To Invest In Right Now: Camping World Holdings, Inc. (CWH)

Advisors’ Opinion:

  • [By Benzinga News Desk]

    Camping World's (NYSE: CWH) analyst quiet period has ended. So far, it has received coverage form four analysts.

    Sell-Side's Most Noteworthy Calls
    Morgan Stanley downgraded Juniper (NYSE: JNPR) to Underweight.
    Guggenheim downgraded MasterCard (NYSE: MA) to Neutral.
    Imperial Capital upgraded Allegion (NYSE: ALLE) to Outperform.
    Summit Redstone upgraded VMware (NYSE: VMW) to Buy.
    Oppenheimer started Twilio (NYSE: TWLO) at Outperform.
    Deal Talk

    Cipher Pharmaceuticals (NASDAQ: CPHR) is said to have hired an investment bank to explore strategic alternatives, according to sources as reported by Reuters on Monday. The sources said a potential sale of the Canada-based company is being considered. Cipher declined comment on the report.

  • [By Elizabeth Balboa]

    Supply could come from any number of industry players, including Winnebago Industries, Inc. (NYSE: WGO), Thor Industries, Inc. (NYSE: THO), Polaris Industries Inc. (NYSE: PII) and Camping World Holdings Inc (NYSE: CWH). However, whether it comes from existing inventory and whether suppliers can meet the demand are yet to be seen.

Hot Blue Chip Stocks To Invest In Right Now: Netease.com Inc.(NTES)

Advisors’ Opinion:

  • [By Sreekanth Anasa]

    Shares of Hangzhou, China-based NetEase Inc (NASDAQ:NTES)popped 14% in the Feb 16th trading session after the company reported stellar Q4 and full-year 2016 earnings on Feb 15th after market close. The Chinese online gaming giant delivered an EPS of $4.30 on revenues of $1.74B beating EPS estimates by $0.86 and revenue estimates by $16oM. NetEase’s revenue grew by an impressive 53.1% YoY for Q4 and 67.7% for the full year 2016. On the back of these strong numbers, NTES stock closed at an all-time high of $298.73 in yesterday’s trading session. NTES stock might have gone up very high too soon. There could be a correction around the corner but still NTES stock is a great long-term proposition with much more upside left. Here’s why.

  • [By Joe Tenebruso]

    Shares ofNetEase (NASDAQ:NTES)popped 20.1% last month, according to data provided byS&P Global Market Intelligence, as the Chinese internet technology company’s strong fourth-quarter earnings report was applauded by investors.

Top 10 Medical Stocks To Invest In 2018

Shares of Edwards Lifesciences (EW) jumped to the top of the S&P 500 today after the medical-device maker offered its 2017 guidance this morning at its investor day.

Getty Images

Shares of Edwards Lifesciences gained 6.7% to $89.31 today, while the S&P 500 rose 0.2% to 2,246.19.

Wells Fargo’sLarry Biegelsen offers his take on Edwards Lifesciences’ guidance:

Edwards Lifesciences Corporation (EW-$83.73; Outperform) provided its 2017 outlook this morning (12/8) ahead of its investor meeting today. As expected, the company highlighted its robust pipeline which should drive strong growth for years to come. However, the company now expects Q4 16 revenue to come in at the low end of the guidance range due to currency and weakness in surgical heart valves. The 2017 guidance was generally strong on the top and bottom line, with both bracketing consensus.

Top 10 Medical Stocks To Invest In 2018: Olympic Steel Inc.(ZEUS)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of Olympic Steel, Inc. (NASDAQ: ZEUS) got a boost, shooting up 17 percent to $22.55. Olympic Steel reported a Q1 net income of $7.7 million, after posting a loss in the year-ago period.

  • [By Lisa Levin]

    Wednesday afternoon, the basic materials shares climbed by 1.09 percent. Meanwhile, top gainers in the sector included Olympic Steel, Inc. (NASDAQ: ZEUS), up 7 percent, and Aluminum Corp. of China Limited (ADR) (NYSE: ACH), up 7 percent.

  • [By Lisa Levin]

    Basic materials sector was the top gainer in the US market on Monday. Top gainers in the sector included Haynes International, Inc. (NASDAQ: HAYN), Cliffs Natural Resources Inc (NYSE: CLF), and Olympic Steel, Inc. (NASDAQ: ZEUS).

Top 10 Medical Stocks To Invest In 2018: Iridium Communications Inc(IRDM)

Advisors’ Opinion:

  • [By Peter Graham]

    Small cap satellite stock Iridium Communications (NASDAQ: IRDM) reportedQ2 2017 earnings before the market opened on Thursday with results beating expectations. Total revenueincreased 2% to $111.6 million which consisted of $86.6 million of service revenue and $25.0 million of revenue related to equipment sales and engineering and support projects.Service revenue, which represents primarily recurring revenue from Iridium’s growing subscriber base, grew 4% and was 78% of total revenue. The Company ended the quarter with 913,000 total billable subscribers, which compares to 823,000 for the year-ago period and is up from 869,000 for the quarter ended March 31, 2017.Total billable subscribers grew 11% year-over-year, driven by growth in M2M and government customers. Net income was $24.8 million versus $26.9 million for the second quarter of 2016. The CEO commented:

  • [By Jim Robertson]

    Trump’s proposal to spin off air traffic control from the Federal Aviation Administration (FAA) bodes well for small cap satellite stock Iridium Communications (NASDAQ: IRDM), but theres a bigger opportunity for the Company in theInternet of Things (IoT) space. Technology company Harris Corporation (NYSE: HRS) is already a leading candidate to supply the FAA with real-time aircraft tracking data in partnership with Iridium Communications with the latter having a joint venture that has partnered with air traffic control authorities in Canada, Italy, Ireland and Denmark to provide air traffic surveillance (in cooperation with Harris).

Top 10 Medical Stocks To Invest In 2018: Quanta Services, Inc.(PWR)

Advisors’ Opinion:

  • [By Chad Tracy]

    TransCanada is not the only company that stands to profit from the possible Keystone XL approval. Refiners such as Valero and LyondellBasell Industries (NYSE: LYB), as well as construction companies Deere & Co. (NYSE: DE) and Quanta Services (NYSE: PWR) all stand to gain if Keystone XL gets the green light.

  • [By Ben Levisohn]

    Clinton 15 stock basket (DBUSCLNT): UnitedHealth Group (UNH), Humana (HUM), McKesson (MCK), Aecom (ACM), Quanta Services (PWR), ExxonMobil (XOM), Alcoa (AA), NextEra Energy (NEE), Cree (CREE), First Solar (FSLR), Facebook (FB), Netflix (NFLX), Prudential Financial (PRU), Citigroup (C), Union Pacific (UNP).

Top 10 Medical Stocks To Invest In 2018: Profire Energy, Inc.(PFIE)

Advisors’ Opinion:

  • [By Monica Gerson]

    Profire Energy, Inc. (NASDAQ: PFIE) is estimated to post its quarterly earnings at $0.00 per share on revenue of $6.74 million.

    Posted-In: Earnings scheduleEarnings News Pre-Market Outlook Markets

Top 10 Medical Stocks To Invest In 2018: GSE Systems, Inc.(GVP)

Advisors’ Opinion:

  • [By Jim Robertson]

    On Thursday, our Under the Radar Moversnewsletter suggestedbuying small cap performance improvement stock GSE Systems (NYSEMKT: GVP):

    GSE Systems is another somewhat-preemptive position; we think the recent support at the 100-day moving average line (gray) and subsequent string of higher lows is telling. There’s a ceiling at $3.27 that needs to be cleared, but we fear waiting on that to happen because once it does, GVP shares could be catapulted to a price we don’t want to chase.

Top 10 Medical Stocks To Invest In 2018: Visa Inc.(V)

Advisors’ Opinion:

  • [By Paul Ausick]

    Of the three other stocks closest to Boeing’s yearly gain, Apple Inc. (NASDAQ: AAPL) added more than 2% to close the week up 51% for the year to date; Caterpillar Inc. (NYSE: CAT) rose by about 0.8% to a gain of more than 48%; and Visa Inc. (NYSE: V) tacked on 0.9% to bring its annual gain to 43.5%.

  • [By Elizabeth Balboa]

    Dozens of others spent more than $1 million, including Ally Financial Inc (NYSE: ALLY), Visa Inc (NYSE: V) and Navient Corp (NASDAQ: NAVI).

    Related Links:

  • [By Paul Ausick]

    The DJIA stock posting the largest daily percentage loss ahead of the close Monday was Visa Inc. (NYSE: V) which traded down 2.43% at $103.00. The stock’s 52-week range is $75.17 to $200.76. Volume was about 40% below the daily average of around 2.6 million. The company had no specific news.

Top 10 Medical Stocks To Invest In 2018: Sonoco Products Company(SON)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Deutsche Bank’s Debbie Jones and team contend that Sonoco’s (SON) sale of its plastic-container business to Australia’s Amcor is a sign that M&A is in the offing. They explain why:

    Sonoco announced (9/1) that it is selling its Rigid Plastics Blow Molding operations to Amcor (AMC.AU) for $280M. The transaction price represents a multiple of ~8.0x LTM EBITDA. The business had annual sales of ~$210M and consisted of six production sites in the US and one in Canada. Blow molding operations represented ~10% of Sonocos Consumer Packaging segment sales and EBITDA. The transaction is expected to close in Q4. We expect the proceeds to be used to for M&A focused in flexible packaging, thermoforming and temperature-assured packaging.

    We dont believe Sonoco considered its blow molding operations essential to its growth strategy. This standalone business is also more capital intensive compared to some of its other plastic packaging businesses and SON held a small position in the overall market. Ultimately, the company decided it wants to focus its capital in higher growth platforms. We do not expect the divestment to reduce resin buying scale for Sonoco’s remaining assets given different resin buying. Note that with the divestiture of blow molding and the Canton closures plant (divested in Feb. 2015), this makes the ~$100M reels business the last standalone business in the portfolio, but we do not expect this to be divested in the near-term unless cash is needed for much larger M&A.

    Shares of Sonoco have gained 1.3% to $52.49 at 2:12 p.m. today.

     

Top 10 Medical Stocks To Invest In 2018: Knowles Corporation(KN)

Advisors’ Opinion:

  • [By Jack Delaney]

    A deal with Facebook Inc. (Nasdaq: FB) brought the little-known Knowles Corp. (NYSE: KN) to investors’ attention today, boosting Knowles Corp. stock by 2.3% as of 12:30 p.m. today (Oct. 30, 2017).

Top 10 Medical Stocks To Invest In 2018: Noah Holdings Ltd.(NOAH)

Advisors’ Opinion:

  • [By Monica Gerson]

    Noah Holdings Limited (ADR) (NYSE: NOAH) is estimated to post financial results for its latest quarter.

    Posted-In: Earnings scheduleEarnings News Pre-Market Outlook Markets

Top 10 Medical Stocks To Invest In 2018: Spark Therapeutics, Inc.(ONCE)

Advisors’ Opinion:

  • [By Jim Robertson]

    On Wednesday, our Elite Opportunity Pronewsletter suggested going long again on small cap gene therapy stock Spark Therapeutics (NASDAQ: ONCE):

    Financially, Spark Therapeutics has over $300M in cash on the books and no debt to speak of yet, which equates to a share price of just over four times cash. The Company has generated over $20M in revenue for the trailing twelve months, and although the Company is expected to continue to lose money for the next few years, any strong clinical data that hits the tape could rocket shares of ONCE overnight, just like we’ve seen with so many others over the years.